The Queensland government has announced the extension of the Johnson & Johnson Innovation Partnering Office at Queensland University of Technology (QUT), which supports the commericalisation of health technology research.
Queensland premier Annastacia Palaszczuk made the announcement as delegates gathered in Brisbane for the AusBiotech National Conference. The state government is providing funding for the office through its Advance Queensland grant program.
The Johnson & Johnson Partnering Office was launched in 2016 to enable innovative research and development for the state’s life sciences industry. Housed at QUT’s Institute of Health and Biomedical Innovation (IHBI), the office serves as a strong platform to identify and nurture life science research collaborations.
The office provides access to knowledge exchange, scouting programs, and scientific, regulatory and commercialisation expertise from the Johnson & Johnson family of companies for academics, entrepreneurs and other early-stage innovators.
“This three-year extension will help deliver new products to the worldwide market, supporting emerging pharmaceutical, medical device and consumer healthcare start-up businesses and researchers across Queensland,” Palaszczuk said.
“This is a commitment to pioneering in our life sciences industry and will support jobs to feed into one of my government’s key priorities to create jobs in a strong economy.”
Queensland is hosting the AusBiotech National Conference for the third time in six years, bringing together hundreds of national and international delegates.
Innovation minister Kate Jones said the government’s $650 million Advance Queensland initiative has backed more than 3600 innovators across the State so far, with their projects supporting more than 12,500 jobs.
“Queensland is internationally-recognised as a centre of life sciences, which is good for our jobs market and for healthcare, medicine and science worldwide,” Jones said.
“Researchers here are world leaders in viral, bacterial and parasitic infection, vaccine research and drug discovery, with tropical diseases a particular strength.”